Xencor, Inc. (XNCR)

NASDAQ: XNCR · IEX Real-Time Price · USD
19.86
-0.57 (-2.79%)
Jul 17, 2024, 4:30 PM EDT - Market closed
-2.79%
Market Cap 1.22B
Revenue (ttm) 162.18M
Net Income (ttm) -133.36M
Shares Out 61.66M
EPS (ttm) -2.19
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 316,083
Open 20.14
Previous Close 20.43
Day's Range 19.72 - 20.75
52-Week Range 16.49 - 26.84
Beta 0.69
Analysts Strong Buy
Price Target 35.63 (+79.41%)
Earnings Date Aug 1, 2024

About XNCR

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, ... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Dec 3, 2013
Employees 280
Stock Exchange NASDAQ
Ticker Symbol XNCR
Full Company Profile

Financial Performance

In 2023, Xencor's revenue was $168.34 million, an increase of 2.28% compared to the previous year's $164.58 million. Losses were -$126.09 million, 128.5% more than in 2022.

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for XNCR stock is "Strong Buy." The 12-month stock price forecast is $35.63, which is an increase of 79.41% from the latest price.

Price Target
$35.63
(79.41% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Xencor Regains CD20 x CD3 Bispecific T-Cell Engager

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, annou...

4 weeks ago - Business Wire

Xencor Reports First Quarter 2024 Financial Results

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today...

2 months ago - Business Wire

Xencor Appoints Bart Cornelissen as Chief Financial Officer

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today...

3 months ago - Business Wire

Xencor to Present at Upcoming Investor Conferences

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today...

5 months ago - Business Wire

Xencor Reports Fourth Quarter and Full Year 2023 Financial Results

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today...

5 months ago - Business Wire

Xencor to Host Webcast to Review Fourth Quarter and Full Year 2023 Financial Results and Provide Vudalimab Clinical Update

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune dis...

5 months ago - Business Wire

Xencor to Present at the 42nd Annual J.P. Morgan Healthcare Conference

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune dise...

7 months ago - Business Wire

Dane Leone Joins Xencor as Senior Vice President, Corporate Strategy

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune dise...

7 months ago - Business Wire

20 favorite small-cap stocks for 2024 among Wall Street analysts

The 2023 stock-market rally has been led by the “Magnificent Seven” companies, which have driven an accelerating upward trend for the large-cap benchmark S&P 500. Shares of smaller and medium-sized co...

7 months ago - Market Watch

Xencor to Present at the Piper Sandler 35th Annual Healthcare Conference

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and a...

8 months ago - Business Wire

Xencor Sells Portion of Royalties and Milestones from Ultomiris® and Monjuvi® to OMERS Life Sciences for $215 Million

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune dise...

9 months ago - Business Wire

Xencor Reports Third Quarter 2023 Financial Results

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and a...

9 months ago - Business Wire

Xencor Presents Preclinical Data from Multiple XmAb® Research Programs at the SITC Annual Meeting

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune dis...

9 months ago - Business Wire

Xencor to Host Third Quarter 2023 Financial Results Webcast and Conference Call on November 7, 2023

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune dis...

9 months ago - Business Wire

Xencor Announces Planned Retirement of Chief Financial Officer John Kuch

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune dise...

9 months ago - Business Wire

Xencor to Present Multiple Posters at the SITC Annual Meeting

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune dise...

10 months ago - Business Wire

Xencor Appoints Barbara J. Klencke, M.D.

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune dise...

10 months ago - Business Wire

Xencor Reports Second Quarter 2023 Financial Results

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and a...

1 year ago - Business Wire

Xencor to Host Second Quarter 2023 Financial Results Webcast and Conference Call on August 3, 2023

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune dis...

1 year ago - Business Wire

Xencor Presents Clinical Results from Phase 1a Study of XmAb®564 at the EULAR 2023 Congress

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and a...

1 year ago - Business Wire

Xencor Reports First Quarter 2023 Financial Results

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and a...

1 year ago - Business Wire

Xencor to Host First Quarter 2023 Financial Results Webcast and Conference Call on May 8, 2023

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune dis...

1 year ago - Business Wire

Xencor Appoints Nancy Valente, M.D., as Chief Development Officer

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune dise...

1 year ago - Business Wire

Xencor Highlights CD28 Bispecific Antibody Platform at AACR Annual Meeting 2023

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune dise...

1 year ago - Business Wire

Xencor to Present Preclinical Data from Novel XmAb® CD28 Bispecific Antibody Programs at the American Association for Cancer Research Annual Meeting 2023

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune dise...

1 year ago - Business Wire